Skip to main content
. Author manuscript; available in PMC: 2020 Jun 1.
Published in final edited form as: Cell Calcium. 2019 Mar 6;80:8–17. doi: 10.1016/j.ceca.2019.03.002

Figure 1. TRPM2 promotes growth of neuroblastoma xenografts and reduces ROS.

Figure 1.

A. Athymic mice were injected in the flank with parental SH-SY5Y cells (Wild type, Wt), cells in which TRPM2 was deleted with CRISPR (two clones, KO-1, KO-2), or scrambled control cells (Scr-1, Scr-2). Representative photographs of tumors removed at 6 weeks after cell injection are shown. In two experiments (n=13–14), p≤0.01 for differences in Scr vs KO tumor volumes and weights. B. ROS levels were measured in SH-SY5Y neuroblastoma cells in which TRPM2 was depleted with CRISPR (two clones, KO-1, KO-2), or scrambled control cells (Scr-1, Scr-2). Cells were loaded with MitoSOX Red and intensity of fluorescence measured with confocal microscopy at baseline or 24 hours after treatment with 0.3 μM doxorubicin. A representative field of cells from each group and statistical analysis from a representative experiment are shown. Mitochondrial ROS were increased in TRPM2 depleted cells at baseline and after doxorubicin treatment. *p<0.05.

HHS Vulnerability Disclosure